The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Exelixis (NASDAQ:EXEL) said on Wednesday that the U.S. FDA has approved cabozantinib for patients 12 years of age and older ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Among patients with ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...